DGAP-News

Novavax Announces Proposed Public Offering of Common Stock

DGAP-News: Novavax, Inc. /
Novavax Announces Proposed Public Offering of Common Stock

04.06.2014 / 22:11

---------------------------------------------------------------------

GAITHERSBURG, Md., 2014-06-04 22:11 CEST (GLOBE NEWSWIRE) --
GAITHERSBURG, Md., June 4, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced that it intends to offer to sell,
subject to market and other conditions, $100 million of its common stock in an
underwritten public offering. As part of this offering Novavax, Inc. intends to
grant the underwriters a 30-day option to purchase up to an additional $15
million of its common stock. The success, the size and the terms of this
offering cannot be guaranteed.

Citigroup and JP Morgan are acting as joint book-running managers of the
offering.

All shares being offered are to be sold by Novavax, Inc., with the net proceeds
from the offering to be used for general corporate purposes, the advancement of
its clinical-stage vaccine candidates and its preclinical research programs,
manufacturing and process development activities, capital expenditures and
other strategic purposes.

The securities described above are being offered by Novavax pursuant to its
registration statement on Form S-3 previously filed and declared effective by
the Securities and Exchange Commission (SEC). This press release does not
constitute an offer to sell or a solicitation of an offer to buy the securities
in the offering, nor shall there be any sale of these securities in any
jurisdiction in which an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such jurisdiction.
The offering may be made only by means of the preliminary prospectus supplement
and the prospectus relating to the proposed offering, copies of which may be
obtained, when available, from Citigroup and JP Morgan, Attention: Citigroup,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717, by telephone at [phone]; or J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or
by telephone: [phone].

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines and vaccine adjuvants to address a broad range of infectious
diseases worldwide. Using innovative proprietary recombinant nanoparticle